文章：

抗肥胖药物与老年女性肥胖相关癌症风险：基于2007–2015年SEER-Medicare数据的倾向评分匹配分析

Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007–2015 SEER-Medicare Data

原文发布日期：11 May 2025

DOI: 10.3390/cancers17101624

类型: Article

开放获取: 是

英文摘要：

Background/Objectives:The increasing prevalence of obesity has led to a growing interest in anti-obesity medications (AOMs). While these medications have shown promise in aiding weight loss, their potential impact on reducing obesity-related cancers (ORCs) incidence remains poorly understood, particularly among women over 65 years of age. This study examined the association between the use of AOMs and the risk of ORCs in this population.Methods:A retrospective cohort study was conducted using 2007–2015 SEER-Medicare data, including 10,830 women aged ≥65 years in a 1:2 propensity-score matching design. The primary exposure was AOM use, with additional analyses focused specifically on phentermine and liraglutide exposure. Conditional multivariable Cox proportional hazards models were conducted.Results:We found an inverse association between the use of AOMs and the risk of ORCs (aHR: 0.78; 95% CI: 0.73–0.84;p< 0.001). Similar findings were observed in cancer-specific sites analysis, advanced-stage ORCs (aHR: 0.76; 95% CI: 0.65–0.89;p< 0.001), breast (aHR: 0.84; 95% CI: 0.77–0.91;p< 0.001), colorectal (aHR: 0.82; 95% CI: 0.71–0.96;p= 0.010), and advanced-stage colorectal cancers (aHR: 0.71; 95% CI: 0.54–0.91;p< 0.001). In secondary analyses, phentermine was inversely associated with the risk of ORCs, breast, and endometrial cancers, but no associations with liraglutide were observed.Conclusions:The use of AOMs, including phentermine, was inversely associated with ORCs and some cancer-specific sites in a cohort of older women. Further prospective studies are warranted to validate these findings among women of different age groups and to identify the underlying biological mechanisms.

摘要翻译： 

背景/目的：随着肥胖患病率的不断上升，人们对抗肥胖药物（AOMs）的关注日益增加。尽管这些药物在辅助减重方面显示出潜力，但其对降低肥胖相关癌症（ORCs）发病率的潜在影响，尤其是在65岁以上女性群体中，目前仍知之甚少。本研究旨在探讨该人群使用AOMs与ORCs风险之间的关联。 方法：本研究采用回顾性队列设计，利用2007-2015年SEER-Medicare数据库，通过1:2倾向评分匹配纳入10,830名年龄≥65岁的女性。主要暴露因素为AOMs的使用，并额外针对芬特明和利拉鲁肽的使用进行了专门分析。采用条件多变量Cox比例风险模型进行统计分析。 结果：研究发现，使用AOMs与ORCs风险呈负相关（调整后风险比[aHR]：0.78；95%置信区间[CI]：0.73–0.84；p < 0.001）。在特定癌症部位分析、晚期ORCs（aHR：0.76；95% CI：0.65–0.89；p < 0.001）、乳腺癌（aHR：0.84；95% CI：0.77–0.91；p < 0.001）、结直肠癌（aHR：0.82；95% CI：0.71–0.96；p = 0.010）以及晚期结直肠癌（aHR：0.71；95% CI：0.54–0.91；p < 0.001）中均观察到类似关联。在次要分析中，芬特明与ORCs、乳腺癌和子宫内膜癌的风险呈负相关，但未观察到利拉鲁肽与癌症风险存在关联。 结论：在老年女性队列中，使用AOMs（包括芬特明）与ORCs及某些特定部位癌症风险呈负相关。有必要开展进一步的前瞻性研究，以在不同年龄组女性中验证这些发现，并揭示其潜在的生物学机制。

原文链接：

Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007–2015 SEER-Medicare Data